Navigation Links
Max Neeman International to Open Phase I/IIa Unit
Date:9/23/2009

RESEARCH TRIANGLE PARK, N.C., Sept. 23 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announced a partnership with Max Healthcare to open a Phase I/IIa clinical trial unit at Max Super Speciality Hospital, New Delhi, India. This proof of concept unit will allow Pharmaceutical, Biotech & Device companies the option to complete a critical part of the development process across multiple therapeutic areas quickly and with the highest quality.

The new Phase I/IIa unit will evaluate compounds/devices developed both in India and in other countries. This unit will provide end-to-end services and will have approximately 24 beds, with plans to expand this number to 50 to meet predicted growth in demand.

This new Phase I/IIa unit will draw on the experience of its partners and the expertise of local clinicians and scientists to deliver studies in accordance with global standards and within the regulatory framework in India.

Our partner Max Healthcare, with over 800 beds and 8 hospitals in Delhi is one of the leading hospital chains in India and has an outstanding reputation and track record for quality health care provision in India.

About Max Healthcare

With over 800 beds and 8 hospitals in Delhi, and with over 1500 physicians and 3000 support staff - Max Healthcare is one of a leading chain of hospitals in India. Its state of the art infrastructure, over 225 ICU beds and most advanced technologies makes it one of the best hospitals in India. http://www.maxhealthcare.in

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India providing a full range of clinical services to global Pharmaceutical, Biotech and Device companies. Operational since 2001, it is an ISO 9001:2000 certified CRO for Monitoring, Site Management and Data Management Services. Presently, it is active in 22 cities with 5 regional offices. Please contact Donald Swankie, Vice President of Business Development for more information (donald.swankie@neeman-medical.com/ +1.919.424.3345). http://www.neeman-medical.com


'/>"/>
SOURCE Max Neeman International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
4. Arrow International Files and Mails Definitive Proxy Materials
5. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
6. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
7. Viragen International to Reverse Split Its Common Stock
8. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
9. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Biosafety and Biosecurity International Conference 2007 to be held in Abu Dhabi from November 12 to 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Research and Markets has announced the addition of the ... ... provides separate comprehensive analytics for the US, Japan ... estimates and forecasts are provided for the period 2015 through 2022. ... data and analytics are derived from primary and secondary research. This ...
(Date:2/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today ... peptide drug candidates, PTG-100 and PTG-200, at the ... and Colitis Organization (ECCO).  The ECCO congress is ... from February 15 – 18, 2017. ... Protagonist drug candidates PTG-100 and PTG-200. PTG-100, a ...
(Date:2/16/2017)... WEST PALM BEACH, Fla. , Feb. 16, ... molecular diagnostics company revolutionizing the development of liquid ... that it has entered into an exclusive license ... who will distribute MDNA,s proprietary liquid biopsy test ... in South Korea . This ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
Breaking Biology Technology:
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
Breaking Biology News(10 mins):